HitGen Inc.
HitGen Inc. is a biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH). HitGen has established a drug discovery research platform for small molecules and nucleic acid drug centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.
Azidation
bromination reaction
palladium catalyzed coupling
High and low temperature reaction kettle, rotary evaporator, extraction kettle, refrigerator, blast drying oven, vacuum drying oven, high performance liquid chromatography, melting point apparatus, ultraviolet detector
Product name *
Quantity *
Product Description *
Add Attachments